SHL Medical welcomes Lyophilization Technology, Inc.

Within its alliance partnership framework, SHL Medical, a world-leading solutions provider of advanced drug delivery systems has entered a non-exclusive strategic partnership with Lyophilization Technology, Inc. (hereafter “LTI”), a contract development and manufacturing organization (CDMO) specializing in lyophilization for preparation of health care products.

Lyophilization is increasingly used in the development of injectable drugs to enhance their shelf life and thermal stability. Traditionally, lyophilized medications were delivered via individual vials of product and diluent that often require healthcare professionals to administer, or complex kits for self administration. With ReuniteTM, SHL Medical recently introduced a dual-chamber cartridge autoinjector supporting automated reconstitution that facilitates the delivery of lyophilized formulations. It features a simple three-step process ensuring accurate dosing with a user-friendly design for safe and effortless self-administration. Reduced contamination potential and increased patient compliance are additional benefits.LTI brings deep expertise in lyophilization, coupled with proven capabilities in product development and process engineering, and preparing dual-chamber cartridges for clinical studies in full compliance with both US and EU regulatory standards.

As the pharmaceutical industry sees a growing demand for patient-friendly administration of lyophilized injectable drugs, SHL Medical and LTI are joining forces to deliver solutions that meet the evolving needs of drug developers. By combining SHL’s new autoinjector platform with LTI’s development capabilities for dual-chamber cartridges, the partnership enables the efficient production of clinical-grade material.

Ralph Howald, SHL Medical’s CTO, commented: “We are excited to partner with Lyophilization Technology, Inc. to further support our customers during the critical and complex phases of feasibility assessments and clinical studies. This collaboration creates meaningful synergies that drive drug delivery innovation, streamline development timelines, and support the advancement of therapies that improve patient outcomes.”

“We value the collaboration with SHL as an industry leader, having a shared vision of providing an effective and economical pathway in developing new product innovations,” said Ed Trappler, President of Lyophilization Technology, Inc. “This provides unique opportunities for delivering life-changing therapies in home healthcare, being safe, effective, and most comfortable to the patient.”